CRISPR Therapeutics AG (CRSP) Research & Development (2015 - 2026)

CRISPR Therapeutics AG has disclosed Research & Development across 12 years of filings, most recently posting $67.2 million for Q2 2026.

• In Q2 2026, Research & Development fell 3.92% year-over-year to $67.2 million; the TTM figure through Jun 2026 stood at $207.6 million (down 29.92% YoY), while the FY2025 annual figure was $284.8 million, down 8.2% from the prior year.
• Research & Development came in at $67.2 million for Q2 2026 at CRISPR Therapeutics AG, down from $68.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $123.2 million in Q2 2022 to a low of $13.0 million in Q4 2025.
• Average Research & Development over 5 years is $83.8 million, with a median of $81.2 million recorded in 2024.
• Year-over-year, Research & Development surged 67.44% in 2022 and tumbled 81.88% in 2025.
• Over 5 years, Research & Development stood at $103.6 million in 2022, then decreased by 8.12% to $95.1 million in 2023, then fell by 24.6% to $71.7 million in 2024, then plunged by 81.88% to $13.0 million in 2025, then jumped by 416.55% to $67.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $67.2 million in Q2 2026, $68.6 million in Q1 2026, and $13.0 million in Q4 2025.